This research study is evaluating the combination of two drugs called GSK1120212 (trametinib)
and GSK2141795 as a possible treatment for recurrent or persistent cervical cancer.
Trametinib and GSK2141795 are drugs that may stop cancer cells from growing. Trametinib is a
MEK inhibitor - it blocks a protein called MEK that is commonly overactive in tumor cells.
GSK2141795 is an AKT inhibitor which blocks a pathway in cancer cells that is commonly
overactive in tumor cells called the PI3kinase pathway. In this research study, the
investigator is looking to see whether the combination of Trametinib and GSK2141795 is useful
in treating recurrent and persistent cervical cancer.
Additionally, the investigator is looking to see if participants whose tumors contain a
particular genetic make-up will have better response to combination trametinib and
GSK2141795. Participants' tumors will be tested for mutations in genes which could make some
cancers more susceptible to trametinib and GSK2141795.